AWMSG issues Final Appraisal Recommendation on bortezomib (Velcade®) subcutaneous injection
Source: All Wales Medicines Strategy Group (AWMSG)
Area: Evidence > Drug Specific Reviews
In its Final Appraisal Recommendation, the All Wales Medicines Strategy Group (AWMSG) is of the opinion that bortezomib (Velcade®) 3.5 mg subcutaneous injection is appropriate for specialist only prescribing within NHS Wales, as an alternative to the intravenous injection, for the following indications:
. treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.
. in combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news
More News: Bone Marrow Transplant | Chemotherapy | Drugs & Pharmacology | Myeloma | Prednisone | Transplants | Velcade